* inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged at least 18 and older. * enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. * previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. * prior covid-19 diagnosis confirmed by patient reported infection followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. * exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. * non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). * ability of subject to understand and the willingness to sign a written informed consent document. * prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. * meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

* inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged at least 18 and older. * enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. * previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. * prior covid-19 diagnosis confirmed by patient reported infection followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. * exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. * non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). * ability of subject to understand and the willingness to sign a written informed consent document. * prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. * meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported infection followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported infection followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sars-cov-2 followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5. patients with severe acute covid-19 requiring hospitalization or icu care are excluded. enrollment could take place 12 weeks after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sars-cov-2 followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sars-cov-2 followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sars-cov-2 followed by confirmatory nucleocapsid antibody testing or a positive sars-cov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

None

None

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 'post-coronavirus disease 19 convalescence at the national institutes of health.' previously diagnosed with mild-moderate covid-19 (who clinical progression scale between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. previously diagnosed with mild-moderate covid-19 (who clinical progression scale32 between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs 33 (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.

inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: stated willingness to comply with all study procedures and availability for the duration of the study. male or female, aged at least 18 and older. enrolled in the screening phase of protocol 000089 post-coronavirus disease 19 convalescence at the national institutes of health. previously diagnosed with mild-moderate covid-19 (who clinical progression scale32 between 2-5). enrollment could take place between 12 weeks and 18 months after the diagnosis of acute covid-19. prior covid-19 diagnosis confirmed by patient reported positive antigen test for sarscov-2 with confirmatory nucleocapsid antibody testing at screening or a positive sarscov-2 pcr test result from the time of infection. exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent pasc symptoms after recovering from a sars-cov-2 infection. these include symptoms such as fatigue, cognitive difficulties, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation or strength. non-negligible pasc symptom severity, as determined using pcfs 33 (minimal score of 2). ability of subject to understand and the willingness to sign a written informed consent document. prior completion of a clinical brain mri after the diagnosis of covid-19, or willingness to complete a brain mri. meets current clinical center hes policy for discontinuing isolation and quarantine for covid-19.